ArticleJournal of the Endocrine Society2023
Prevalence, Incidence, and Clinical Characteristics of Thyroid Eye Disease in Japan.
Article in Journal of the Endocrine Society, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Safety profile of intravenous methylprednisolone therapy for thyroid eye disease: a multicenter retrospective study.Japanese journal of ophthalmology · 2026Article
- Association of smoking with thyroid eye disease and related diplopia in a Japanese population: a retrospective study.Japanese journal of ophthalmology · 2026Article
- A Korean Clinical Practice Framework for Thyroid Eye Disease: Integrating International Recommendations with Survey-Informed Consensus.Endocrinology and metabolism (Seoul, Korea) · 2026Article
- Validation and Development of Claims-Based Algorithms for Identifying Thyroid Eye Disease Using the IRIS Registry-Komodo Linked Database.Journal of clinical medicine · 2026Article
- Visual cueing and adaptive learning for teaching thyroid eye disease diagnostic assessment to ophthalmology residents.Frontiers in medicine · 2026Article
- Safety, pharmacokinetics, and potential benefits of TSH-receptor-specific monoclonal autoantibody K1-70Endocrine journal · 2025Article
- Epidemiology and Management of Moderate to Severe Thyroid Eye Disease in the United States: Analysis of a Healthcare Claims Database.Clinical endocrinology · 2025Article
- A randomised, double-masked, placebo-controlled trial evaluating the efficacy and safety of teprotumumab for active thyroid eye disease in Japanese patients.The Lancet regional health. Western Pacific · 2025Article
- Article
- Prevalence and characteristics of postoperative and nonoperative chronic hypoparathyroidism in Japan: a nationwide retrospective analysis.JBMR plus · 2024Article
- Automated eyeball volume measurement based on CT images using neural network-based segmentation and simple estimation.Scientific reports · 2024Article
- Prevalence, Incidence, and Clinical Characteristics of Thyroid Eye Disease in Japan.Journal of the Endocrine Society · 2023Article
- Multimodal MRI reveals structural and functional alterations in thyroid-associated ophthalmopathy.Frontiers in neurologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Although thyroid eye disease (TED) can impact social and psychological well-being, the epidemiological evidence of TED is lacking in Japan. Methods: Nationwide claims databases provided by JMDC Inc. and Medical Data Vision Co., Ltd. and national population statistics are used. Three TED definitions ranging from a strict definition only including a TED diagnosis to a broad definition including a TED diagnosis and considering ocular symptoms are considered. The proportion of patients by severity and disease activity are estimated based on definitions that would allow identification of those patients within the claims data. Results: The incidence rate per 100 000 person-years ranged from 7.3 to 11.1 for the strict and broad TED definitions, respectively. For fiscal year 2020 (April 2020 to March 2021) the prevalence rate ranged between 24.65 (strict TED) and 37.58 (broad TED) per 100 000 persons. These correspond to 25 383 and 38 697 patients for the strict and broad TED definitions, respectively. Regardless of the definition used, a predominance of female patients was observed, and the highest burden of the disease was seen in the age group of 35 to 59. Mild and inactive forms of TED were predominant (about 85% and 74%, respectively). Conclusion: The incidence and prevalence of TED in Japan were 7.3 to 11.1 per 100 000 person-years and 24.65 to 37.58 per 100 000 persons, respectively. The robust results of this database study add valuable real-world evidence on the incidence and prevalence of TED in Japan.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.